Why the study?
Is antihypertensive treatment cost-effective across different age groups?
Is antihypertensive treatment cost-effective across different age groups?
Antihypertensive treatment is more cost-effective in patients over 45 years of age due to their higher absolute cardiovascular risk.
May warrant age-based antihypertensive prioritization after 45; leaves open prospective cost-effectiveness trials in younger adults.
The benefits of antihypertensive treatment are influenced by both the absolute initial cardiovascular risk, and the relative reduction. Because age is a major determinant of the absolute cardiovascular risk, and because the strategies for hypertension diagnosis and treatment are not very much influenced by age, hypertension management appears to be more cost-effective after the age of 45, in both men and women. Below this age, the absolute gain in life-years seems to be smaller, and sensitivity analysis demonstrate an important influence on the results of assumptions about the effects of treatment on quality of life and the discounting rate.
No takes yet. Share an insight, caveat, or question.
Joël Ménard (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: